Skip to content

AIM round-up: Nanosynth, Eqtec, Tekcapital


Despite a promising start to the week, London’s AIM index gave back early gains heading into the close to reach the bell less than one point higher at 875.6

  • Nanosynth +67%
  • Eqtec +26%
  • Tekcapital +13%
  • Active Energy -16%
  • Shield Therapeutics -15%

Nanosynth LON:NNN topped the board today, advancing 67% after publishing a strategic update this morning. The company is undertaking a turn around plan and the note acknowledges shareholder frustration with the pace of change, but a significant volume of shares changed hands during the session, returning the stock to levels not seen since late May.

Eqtec LON:EQT also made progress, adding 26% by the bell. There’s no fresh news here, but announcements last week regarding a technology partner may pave the way for stronger prospects in the coming months.

A notable mention for Tekcapital LON:TEK, which this morning signalled the possible IPO of a majority owned portfolio company, MicroSalt. They have in turn just signed their first B2B distribution deal in the US. Shares sat some 13% higher at the close.

Active Energy LON:AEG was the worst performer, off 16% after an AGM statement and strategic update was published this morning. Deal flow was however limited and the spread accounst for the vast majority of the losses.

Shield Therapeutics LON:STX also struggled, sliding 15% by the bell, extending those losses we reported on at the end of last week. Investors seemingly remain wary over the outlook.

Looking for great investing ideas? Sign up to our free newsletter.

Join us on WhatsApp

This article does not constitute investment advice. Make sure you do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

CME Group
FP Markets
Back To Top